Valsts: Eiropas Savienība
Valoda: angļu
Klimata pārmaiņas: EMA (European Medicines Agency)
Dexmedetomidine hydrochloride
Orion Corporation
N05CM18
dexmedetomidine
Psycholeptics
Conscious Sedation
For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
Revision: 16
Authorised
2011-09-15
24 B. PACKAGE LEAFLET 25 PACKAGE LEAFLET: INFORMATION FOR THE USER DEXDOR 100 MICROGRAMS/ML CONCENTRATE FOR SOLUTION FOR INFUSION dexmedetomidine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Dexdor is and what it is used for 2. What you need to know before you are given Dexdor 3. How to use Dexdor 4. Possible side effects 5. How to store Dexdor 6. Contents of the pack and other information 1. WHAT DEXDOR IS AND WHAT IT IS USED FOR Dexdor contains an active substance called dexmedetomidine which belongs to a medicine group called sedatives. It is used to provide sedation (a state of calm, drowsiness or sleep) for adult patients in hospital intensive care settings or awake sedation during different diagnostic or surgical procedures. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DEXDOR YOU MUST NOT BE GIVEN DEXDOR - if you are allergic to dexmedetomidine or any of the other ingredients of this medicine (listed in section 6) - if you have some disorders of heart rhythm (heart block grade 2 or 3) - if you have very low blood pressure which does not respond to treatment - if you have recently had a stroke or other serious condition affecting blood supply to the brain. WARNINGS AND PRECAUTIONS Before you have this medicine, tell your doctor or nurse if any of the following apply as Dexdor should be used cautiously: - if you have an abnormally slow heart rate (either due to illness or high levels of physical fitness) as it may increase the risk for cardiac arrest - if you have low blood pressure - if you have low blood volume, for example after bleeding - if you have certain heart disorders - if you are elderly - if you have a neurological disorder (for instance head o Izlasiet visu dokumentu
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Dexdor 100 micrograms/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of concentrate contains dexmedetomidine hydrochloride equivalent to 100 micrograms dexmedetomidine. Each 2 ml ampoule contains 200 micrograms of dexmedetomidine. Each 2 ml vial contains 200 micrograms of dexmedetomidine. Each 4 ml vial contains 400 micrograms of dexmedetomidine. Each 10 ml vial contains 1 000 micrograms of dexmedetomidine. The concentration of the final solution after dilution should be either 4 micrograms/ml or 8 micrograms/ml. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). The concentrate is a clear, colourless solution, pH 4.5–7.0 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3). For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION FOR SEDATION OF ADULT ICU (INTENSIVE CARE UNIT) PATIENTS REQUIRING A SEDATION LEVEL NOT DEEPER THAN AROUSAL IN RESPONSE TO VERBAL STIMULATION (CORRESPONDING TO RICHMOND AGITATION-SEDATION SCALE (RASS) 0 TO -3). For hospital use only. Dexdor should be administered by healthcare professionals skilled in the management of patients requiring intensive care. Posology Patients already intubated and sedated may switch to dexmedetomidine with an initial infusion rate of 0.7 micrograms/kg/h which may then be adjusted stepwise within the dose range 0.2 to 1.4 micrograms/kg/h in order to achieve the desired level of sedation, depending on the patient’s response. A lower starting infusion rate should be considered for frail patients. Dexmedetomid Izlasiet visu dokumentu